Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 76, Issue , 2013, Pages 13-20

  Antunes, Marina Venzon ^a,b   Rosa, Daniela Dornelles ^b,c   Viana, Tamyris dos Santos ^a   Andreolla, Huander ^c   Fontanive, Tiago Ozelame ^b   Linden, Rafael ^a  

^a UNIVERSIDADE FEEVALE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Clinical Hospital of Porto Alegre   (Brazil)

Author keywords

4 Hydroxytamoxifen; Endoxifen; HPLC UV; N desmethyltamoxifen; Tamoxifen

Indexed keywords

ACETONITRILE; AFIMOXIFENE; DRUG METABOLITE; ENDOXIFEN; NORTAMOXIFEN; PHOSPHATE BUFFERED SALINE; TAMOXIFEN;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 84872018232     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.12.005     Document Type: Article

References (35)

1. Ahsen N.V., Binder C., Brockmoller J., Oellerich M. CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?. J. Lab. Med. 2009, 33:1-9.
2. Beverage J.N., Sissung T., Sion A.M., Danesi R., Figg W. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J. Pharm. Sci. 2007, 96:2224-2231.
3. Teunissen S.F., Rosing H., Koornstra R.H.T., Linnb S.C., Schellensc J.H.M., Schinkel A.H., Beijnen J.H. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatgr. B 2009, 877:2519-2529.
4. Irvin W.J., Walko C.M., Weck K.E., Ibrahin J.G., Chiu W.K., Dees E.C., Moore S.G., Olajide O.A., Grahan M.L., Canale S.T., Raab R.E., Corso S.W., Peppercorn J.M., Anderson S.M., Friedman K.J., Ogburn E.T., Desta Z., Flockhart D.A., McLeod H.L., Evans J.P., Carey L.A. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 2011, 29:3232-3239.
5. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler Z., Weinshilboum R.M., Rae J.M., Hayes D.F., Flockhart D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 2005, 97:30-39.
6. Antunes M.V., Linden R., Santos T.V., Wallemacq P., Haufroid V., Classen J.F., Andreolla H., Costa N., Fontanive T.O., Rosa D.D. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther. Drug Monit. 2012, 34:422-431.
7. Gallicchio L., Lord G., Tkaczuk K., Danton M., Lewis L.M., Lim C.K., Flaws J.A. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res. Treat. 2004, 85:89-97.
8. Gjerde J., Kisanga E.R., Hauglid M., Holm P.I., Mellgren G., Lien E.A. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2005, 1082:6-14.
9. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff M., Wu L., Hillman G., Hayes D.F., Stearns V., Flockhart D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 2006, 80:61-74.
10. Newman W.G., Hadfield K.D., Latif A., Roberts S.A., Shenton A., McHague C., Lalloo F., Howell Evans S.G. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 2008, 14:5913-5918.
11. Girault J., Istin B., Fourtillan J.B. Quantitative measurement of 4-hydroxy tamoxifen in human plasma and mammary tumours by combined gas chromatography/negative chemical ionization mass spectrometry. Biol. Mass Spectrom. 1993, 22:395-402.
12. Jones R.M., Yuan Z.X., Lamb J.H., Lim C.K. One-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism. J. Chromatogr. A 1996, 722:249-255.
13. MacCallum J., Cummings J., Dixon J.M., Miller W.R. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J. Chromatogr. B 1996, 678:317-323.
14. Yazigi A., Legayada E. Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. J. Chromatogr. B 1997, 691:457-462.
15. Lim H.S., Ju L.H., Seok L.K., Sook L.E., Jang I.J., Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 2007, 25:3837-3845.
16. Manns J.E., Hanks S., Brown J.E. Optimised separation of E- and Z-isomers of tamoxifen and its principal metabolites using reversed-phase high performance liquid chromatography. J. Pharm. Biomed. Anal. 1998, 16:847-852.
17. Lee K.H., Ward B.A., Desta Z., Flockhart D.A., Jones D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B 2003, 791:245-253.
18. Furlanut M., Franceschi L., Pasqual E., Bacchetti S., Poz D., Giorda G. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther. Drug Monit. 2007, 29:349-352.
19. Zhu Y.B., Zhang Z., Zou J.J., Yu Z.X., Xiao D.W. Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study. J. Pharm. Biom. Anal. 2008, 46:349-355.
20. John B.A., Brodie R.R., Baldock G.A., McBurney A., Chasseaud L.F., Jank P., Von Niecieki A. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 2002, 32:699-713.
21. Poon G.K., Walter B., Lonning P.E., Horton M.N., McCague R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 1995, 23:377-382.
22. Williams L.D., Twaddle N.C., Churchwell M.I., Doerge D.R. Quantification of tamoxifen and metabolites and soy isoflavones in human plasma using liquid chromatography with electrospray ionization tandem mass spectrometry. J. AOAC Int. 2006, 89:1168-1173.
23. Esteve-Romero J., Ochoa-Aranda E., Bose D., Rambla-Alegre M., Peris-Vicente J., Martinavarro-Dominquez A. Tamoxifen monitoring studies in breast cancer patients by micellar liquid chromatography. Anal. Bioanal. Chem. 2010, 397:1557-1561.
24. Teunissen S.F., Rosing H., Schinkel A.H., Schellens J.H.M., Beijnen J.H. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. Anal. Chim. Acta 2010, 683:21-37.
25. Lien E.A., Wester K., Lonning P.E., Solheiml E., Ueland P.M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 1991, 63:641-645.
26. Pragst F., Herzler M., Erxleben B.T. Systematic toxicological analysis by high-performance liquid chromatography with diode array detection (HPLC-DAD). Clin. Chem. Lab. Med. 2004, 42:1325-1340.
27. Almeida A.M., Castel-Branco M.M., Falcão A.C. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2002, 774:215-222.
28. Shah V.P., Midha K.K., Findlay J.W.A., Hil H.M., Hulse J.D., McGilveray J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
29. Kisanga E.R., Gjerde J., Guerrieri-Gonzaga A., Pigatto P., Pesci-Feltri A., Robertson C., Serrano D., Pelosi G., Decensi A., Lien E.A. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin. Cancer Res. 2004, 10:2336-2343.
30. Furr B.J.A., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 1984, 25:127-205.
31. Dowsett M., Cuzick J., Howell A., Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'arimidex™ and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer 2001, 85:317-324. The ATAC Trialists' Group.
32. Hutson P.R., Love R.R., Havighurst T.C., Rogers E., Cleary J.F. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin. Cancer Res. 2005, 11:8722-8727.
33. Sheth H.R., Lord G., Tkaczuk K., Danton M., Lewis L.M., Langenberg P.P., Lim C.K., Flaws J.A. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J. Womens Health (Larchmt) 2003, 12:799-808.
34. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95:1758-1764.
35. Mürdter T.E., Schroth W., Bacchus-Gerybadze L., Winter S., Heinkele G., Simon W., Fasching P.A., Fehm T., Eichelbaum M., Schwab M., Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 2011, 89:708-717. German Tamoxifen and AI Clinicians Group.